Results for tag: "Colorectal Cancer Diagnostics"

Within the field of diagnostics, the Colorectal Cancer Diagnostics market encompasses a variety of tools and test types designed to detect colorectal cancer (CRC) at different stages of disease progression. This segment of medical diagnostics includes fecal occult blood tests for screening purposes, colonoscopies and sigmoidoscopies for direct visualization and polyp biopsy, as well as molecular tests such as gene expression profiling and liquid biopsy for more detailed characterization of the cancer. This market is driven by technological advancements that aim to provide earlier detection and more personalized treatment, increasing awareness of colorectal cancer screening, and enhancements in non-invasive diagnostic methods which are more acceptable to patients. The adoption of these diagnostic technologies varies depending on healthcare infrastructures, availability, and guidelines that determine recommended screening intervals and methods. There are several notable companies in the Colorectal Cancer Diagnostics market that offer products across various testing modalities. Some of these include Roche Diagnostics, known for their molecular tests and immunochemical fecal occult blood tests; Exact Sciences, which offers non-invasive stool-based DNA testing; and Quest Diagnostics, providing laboratory testing services including tumor biomarker tests. Other players include Genomic Health, with their Oncotype DX colon cancer assay, and Medtronic, offering advanced endoscopic systems used during diagnostic procedures such as colonoscopy. Each company contributes to a diversified field seeking to improve early detection and outcomes for patients with colorectal cancer. Show Less Read more